Business
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program€25 million potential financing opportunity: Up to 50% of the Company's
About this update from Cosmos Health Inc.
[{"type":"text","content":"Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program€25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D programInstitutional-grade capital: Potential long-term, attractively structured financing from the EU's premier development bankR&D acceleration: Strengthens and expands the Company's development pipeline across its portfolioValue creation catalyst: Landmark funding opportunity supporting long-term innovation and growth CHICAGO, IL / ACCESS Newswire / May 14, 2026 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company\") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development (R&D) financing program with the European Investment Bank (EIB), the financing arm of the European Union and one of the world's largest multilateral lenders.In connection with this initiative, Cana Laboratories has entered into an advisory agreement with the EIB to support the Company's progress under the EIB-backed financing program. The agreement represents an important milestone for the Company and reflects the alignment of its R&D initiatives with the EIB's evaluation criteria. Cosmos Health believes the process could support access to long-term institutional financing on attractive terms with limited dilution.The program, under the EIB's Venture Debt scheme, is designed to position the Company for a potential opportunity to access up to 50% of its planned €50 million (approximately $59 million) R&D program, representing up to €25 million (approximately $29 million) in potential financing, upon the achievement of certain milestones. There can be no assurances that the financing will be obtained in part or in full.Potential funding under the EIB's Venture Debt scheme is expected to significantly accelerate Cosmos Health's expanding AI-powered R&D pipeline across multiple therapeutic areas. These include CCX0722, the Company's proprietary weight management solution, as well as oncology programs targeting prostate, ovarian, and colorectal cancers, in addition to initiatives in multiple sclerosis, gliomas, hematologic malignancies, and allergic inflammation.Greg Siokas, CEO of Cosmos Health, stated: \"Securing this agreement mark...